On June 30, 2026, Color Health — the virtual cancer clinic that serves employer, health-plan, and public-sector populations — announced it is offering the Onclarity HPV Self-Collection Kit through its platform, an FDA-cleared at-home swab test that detects 14 high-risk HPV genotypes and individually identifies six specific high-risk strains. The kit is supplied via a partnership in the Waters Corporation diagnostics orbit (Waters Advanced Diagnostics / SNT Biotech), and Color wraps it in oncologist-led clinical follow-up rather than selling it as a standalone test.

Why It Matters

Cervical-cancer screening sits squarely at the intersection of sexual and reproductive health, and at-home HPV self-collection is one of the highest-leverage femtech tools to close screening gaps — particularly for people who avoid speculum-based exams or lack easy clinic access. Embedding the swab inside an employer- and payer-facing virtual clinic (rather than a DTC kit) is the strategically interesting part: it routes the test through covered benefits and guarantees clinical follow-up, addressing the long-standing critique that at-home tests too often dead-end at a positive result with no care pathway. For the broader sexual-health diagnostics market, it's another sign that the future of intimate-health testing is self-collection at home plus a coordinated clinical wrapper.

The differentiator is extended genotyping. Traditional cervical-cancer screening clumps high-risk HPV strains into one or two broad groups; Onclarity isolates individual genotypes beyond the familiar HPV 16, 18, and 45, enabling more precise risk stratification and tailored follow-up. "Despite cervical cancer being preventable, a woman dies from the disease every 90 seconds," said Dr. Jeff Andrews, VP of medical sciences at Waters Advanced Diagnostics, arguing that at-home self-collection removes the access barriers — scheduling, discomfort, clinic distance — that keep many people from getting screened at all.

Color says its model pairs the test with follow-up through its ASCO-certified Virtual Cancer Clinic, reporting a 77% increase in screening adherence, 100% clinical follow-up for every abnormal result, and a 66% reduction in time from abnormal result to cancer diagnosis. The launch lands the same week SNT Biotech and Waters publicized the broader push to bring comprehensive FDA-cleared at-home HPV screening to US patients.

Sources

Update — 2026-06-30

Initial entry — story first created.

Update — 2026-08-31

Same kit, bigger front door. On August 27, 2026, LetsGetChecked — now operating as part of Fuze Health — announced it is offering the Onclarity HPV Self-Collection Kit, tested with the BD Onclarity HPV Assay, describing it as "the most comprehensive FDA-cleared at-home HPV screening tool available in the U.S. today." The announcement came via Business Wire out of West Chester, Ohio, and names Waters Corporation as the partner, the same diagnostics relationship behind Color Health's June rollout.

The significant part is the channel, not the technology. Color Health routes the kit through an employer- and payer-facing virtual cancer clinic. LetsGetChecked runs one of the largest at-home testing operations in the US — in-house kit manufacturing and distribution, its own CLIA-certified laboratory, board-certified telehealth support and affiliate pharmacy services — and sells both direct to consumers and to a stated 5,000+ organizations. The same extended-genotyping assay is now available through a materially wider distribution surface, with treatment follow-up attached on the same platform.

That matters against the NHS England at-home HPV rollout Afterglow covered on August 25: two of the largest self-collection distribution pushes in the category landed within 48 hours of each other, one public and mailed to 4 million non-attenders, one commercial and bundled with telehealth. The competitive question for the next year is whether HPV self-collection settles as a covered benefit routed through employers and payers, a public-health mail-out, or a DTC purchase — because the three models imply very different unit economics for everyone building in intimate-health diagnostics.

New Sources